These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Meibohm B; Derendorf H Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388 [TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic Models of Indirect Effects and Irreversible Inactivation with Turnover: Applicability to Mechanism-Based Modeling of Gene Silencing and Targeted Protein Degradation. Wang AF; Ayyar VS J Pharm Sci; 2024 Jan; 113(1):191-201. PubMed ID: 37884193 [TBL] [Abstract][Full Text] [Related]
13. Assessment of basic indirect pharmacodynamic response models with physiological limits. Yao Z; Krzyzanski W; Jusko WJ J Pharmacokinet Pharmacodyn; 2006 Apr; 33(2):167-93. PubMed ID: 16547797 [TBL] [Abstract][Full Text] [Related]
14. Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. Sharma A; Ebling WF; Jusko WJ J Pharm Sci; 1998 Dec; 87(12):1577-84. PubMed ID: 10189270 [TBL] [Abstract][Full Text] [Related]
17. Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics. Minto CF; Schnider TW; Gregg KM; Henthorn TK; Shafer SL Anesthesiology; 2003 Aug; 99(2):324-33. PubMed ID: 12883405 [TBL] [Abstract][Full Text] [Related]